The industry is at a unique crossroads: pharmaceutical and digital therapeutic (DTx) companies have begun to act on their ambition to advance digital therapeutics—but the path to successful alliances and, importantly, scale remains uncertain. As a follow up to our recent research on building pharma-DTx alliances, we sat down with two leaders to get their perspective on:
- The dos and don’ts of pharma-DTx partnerships
- Evidence standards for digital therapeutics
- Channel pathways and business models for DTx companies
- Assessing the value of working with pharma as a DTx company
Hear from ZS’ Paul Darling, Novo Nordisk’s Amy West, Pear Therapeutics’ Corey McCann, and Rock Health’s Megan Zweig in our latest podcast episode.